Search

Introduction: The A2A adenosine receptor (A2AAR) is expressed in brain, vasculature and immune cells. According to the alterations of the A2AAR expression in multiple diseases, it is a highly attractive diagnostic and therapeutic target. We developed the A2AAR-specific PET radiotracer [18F]FLUDA and investigated it in healthy mice and piglets, in a rotenone-based mouse model of Parkinson’s disease (RMMPD) and in transgenic mice overexpressing the human A2AAR in heart (TG) [1 3]. Methods: On the basis of a one-pot two-step radiofluorination procedure, a remotely controlled automated radiosynthesis of [18F]FLUDA using the TRACERlab FX2N synthesis module was developed. In vitro autoradiography was performed with cryosections of tissue from animal models. In vivo stability was investigated in mouse by radio-HPLC analyses of blood plasma and brain homogenates. The biodistribution was investigated by dynamic PET/MR studies in healthy mice and piglets under control and blocking conditions (vehicle vs. blocking with 2.5 mg/kg tozadenant and/or 1.0 mg/kg istradefylline) and in both mouse models. The binding potential (BPND) in vivo was calculated using the simplified reference tissue modelling with the cerebellum as reference region. A single dose acute toxicity study was performed in Wistar rats according to the ICH guideline M3(R2). PET-derived radiation dosimetry was estimated in piglets. Results: A reliable and reproducible procedure for the automated production of [18F]FLUDA was successfully established (Fig. 1A) [4]. In vitro autoradiography revealed highly selective binding and high affinity of [18F]FLUDA towards the A2AAR of the three species (KD values 0.7-5.9 nM, Fig. 1B). At 15 min after i.v. injection of [18F]FLUDA in mice, the parent fraction accounted for about 100% in brain and 71% in plasma. PET studies confirmed the specific binding of [18F]FLUDA in vivo to the striatal A2AAR in mice and piglets (BPND=3.9 and 1.3, Fig. 1C). The availability of A2AAR in the P

Introduction: The A2A adenosine receptor (A2AAR) is expressed in brain, vasculature and immune cells. According to the alterations of the A2AAR expression in multiple diseases, it is a highly attractive diagnostic and therapeutic target. We developed the A2AAR-specific PET radiotracer [18F]FLUDA and investigated it in healthy mice and piglets, in a rotenone-based mouse model of Parkinson’s disease (RMMPD) and in transgenic mice overexpressing the human A2AAR in heart (TG) [1 3]. Methods: On the basis of a one-pot two-step radiofluorination procedure, a remotely controlled automated radiosynthesis of [18F]FLUDA using the TRACERlab FX2N synthesis module was developed. In vitro autoradiography was performed with cryosections of tissue from animal models. In vivo stability was investigated in mouse by radio-HPLC analyses of blood plasma and brain homogenates. The biodistribution was investigated by dynamic PET/MR studies in healthy mice and piglets under control and blocking conditions (vehicle vs. blocking with 2.5 mg/kg tozadenant and/or 1.0 mg/kg istradefylline) and in both mouse models. The binding potential (BPND) in vivo was calculated using the simplified reference tissue modelling with the cerebellum as reference region. A single dose acute toxicity study was performed in Wistar rats according to the ICH guideline M3(R2). PET-derived radiation dosimetry was estimated in piglets. Results: A reliable and reproducible procedure for the automated production of [18F]FLUDA was successfully established (Fig. 1A) [4]. In vitro autoradiography revealed highly selective binding and high affinity of [18F]FLUDA towards the A2AAR of the three species (KD values 0.7-5.9 nM, Fig. 1B). At 15 min after i.v. injection of [18F]FLUDA in mice, the parent fraction accounted for about 100% in brain and 71% in plasma. PET studies confirmed the specific binding of [18F]FLUDA in vivo to the striatal A2AAR in mice and piglets (BPND=3.9 and 1.3, Fig. 1C). The availability of A2AAR in the P

The cerebral expression of the A2A adenosine receptor (A2AAR) is altered in neurodegenerative disorders diseases such as Parkinson's (PD) or Huntington’s (HD) diseases, making these recep-tors an attractive diagnostic and therapeutic target. We aimed to further investigate the pharma-cokinetic properties in the brain of our recently developed A2AAR specific antagonist radioligand [18F]FLUDA. For this purpose, we retrospectively analysed dynamic PET studies of healthy mice and rotenone-treated mice, and undertook dynamic PET studies with healthy pigs. We performed analysis of mouse brain time-activity curves to calculate the mean residence time (MRT) by non-compartmental analysis and the binding potential (BPND) of [18F]FLUDA using the simplified reference tissue model (SRTM). For the pig studies, we performed a Logan graphical analysis to calculate the radiotracer distribution volume (VT) at baseline and under blocking conditions with tozadenant. The MRT of [18F]FLUDA in the striatum of mice was decreased by 30 % after treatment with the A2AAR antagonist, istradefylline. Mouse results showed the highest BPND (3.9 to 5.9) in the striatum. SRTM analysis showed a 20% lower A2AAR availability in the rotenone-treated mice compared to the control-aged group. Tozadenant treatment significantly decreased the VT (14.6 vs. 8.5 mL · g-1) and BPND values (1.3 vs. 0.3) in pig striatum. This study confirms the target specificity and a high BPND of [18F]FLUDA in the striatum. We conclude that [18F]FLUDA is a suitable tool for the non-invasive quantitation by PET of altered A2AAR expression in neurodegenerative diseases such as PD and HD.

Purpose: The adenosine A2A receptor has emerged as a therapeutic target for multiple diseases, and thus the non-invasive imaging of the expression or occupancy of the A2A receptor has potential to contribute to diagnosis and drug development. We aimed at the development of a metabolically stable A2A receptor radiotracer and report herein the preclinical evaluation of [18F]FLUDA, a deuterated isotopologue of [18F]FESCH. Methods: [18F]FLUDA was synthesized by a two-step one-pot approach and evaluated in vitro by autoradiographic studies as well as in vivo by metabolism and dynamic PET/MRI studies in mice and piglets under baseline and blocking conditions. A single-dose toxicity study was performed in rats. Results: [18F]FLUDA was obtained with a radiochemical yield of 19% and molar activities of 72 180 GBq/µmol. Autoradiography proved A2A receptor-specific accumulation of [18F]FLUDA in the striatum of mouse and pig brain. In vivo evaluation in mice revealed improved stability of [18F]FLUDA compared to [18F]FESCH, resulting in the absence of brain-penetrant radiometabolites. Furthermore, the radiometabolites detected in piglets are expected to have a low tendency for brain penetration. PET/MRI studies confirmed high specific binding of [18F]FLUDA towards striatal A2A receptor with a maximum specific-to-non-specific binding ratio in mice of 8.3. The toxicity study revealed no adverse effects of FLUDA up to 30 µg/kg, ~ 4000-fold the dose applied in human PET studies using [18F]FLUDA. Conclusions: The new radiotracer [18F]FLUDA is suitable to detect the availability of the A2A receptor in the brain with high target specificity. It is regarded ready for human application.

Cyclic nucleotide phosphodiesterases (PDEs) represent one of the key targets in the research field of intracellular signaling related to the second messenger molecules cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP). Hence, non-invasive imaging of this enzyme class by positron emission tomography (PET) using appropriate isoform-selective PDE radioligands is gaining importance. This methodology enables the in vivo diagnosis and staging of numerous diseases associated with altered PDE density or activity in the periphery and the central nervous system as well as the translational evaluation of novel PDE inhibitors as therapeutics. In this follow-up review, we summarize the efforts in the development of novel PDE radioligands and highlight (pre-)clinical insights from PET studies using already known PDE radioligands since 2016.

The adenosine A2A receptor (A2AR) represents a potential therapeutic target for neurodegenerative diseases. Aiming at the development of a positron emission tomography (PET) radiotracer to monitor changes of receptor density and/or occupancy during the A2AR-tailored therapy, we designed a library of fluorinated analogs based on a recently published lead compound. Among those, the highly affine 4-fluorobenzyl derivate (PPY1; Ki(hA2AR) = 5.3 nM) and the 2-fluorobenzyl derivate (PPY2; Ki(hA2AR) = 2.1 nM) were chosen for 18F-labeling via an alcohol-enhanced copper-mediated procedure starting from the corresponding boronic acid pinacol ester precursors. Investigations of the metabolic stability of [18F]PPY1 and [18F]PPY2 in CD-1 mice by radio-HPLC analysis revealed parent fractions of more than 76% of total activity in the brain. Specific binding of [18F]PPY2 on mice brain slices was demonstrated by in vitro autoradiography. In vivo PET/magnetic resonance imaging (MRI) studies in CD-1 mice revealed a reasonable high initial brain uptake for both radiotracers, followed by a fast clearance.

Introduction The A2AR has emerged as a potential therapeutic target due to its involvement in basic functions of the neuronal, cardiovascular and immune systems. Blockade of A2AR is regarded as potential tool related to CAR T-cell immunotherapy of cancer. Furthermore, A2AR are believed to regulate myocardial oxygen demand and to increase coronary circulation by vasodilation. With regard to Parkinson’s disease A2AR antagonists, such as the FDA approved Nourianz®, are used as an adjunctive treatment to levopoda®. Therefore noninvasive imaging to monitor changes of receptor density and/or occupancy during the A2aR-tailored therapy is of utmost importance. We recently developed the A2AR PET radiotracer [18F]FLUDA which demonstrated superior pharmacokinetic properties among the radiotracers available. Towards its clinical translation, an automated radiosynthesis was developed and the radiotracer was fully characterized in vitro and in vivo including toxicity and dosimetry1 studies. Methods The binding affinity (Ki) of FLUDA towards the human A2AR and A1R subtypes was estimated in vitro by competitive radioligand binding assays. In addition, selectivity studies were performed. An automated two-step one-pot radiosynthesis of [18F]FLUDA was developed. In vitro autoradiography was performed on cryosections of mice brain. Dynamic PET/MR studies under baseline and blocking conditions were assessed. The time-activity curves of the SUV ratio (SUVR) of striatum over cerebellum were used as measure for specific uptake. Metabolism was investigated in CD-1 mice via radio-HPLC analysis of extracted plasma and brain samples. Single-dose acute toxicity of FLUDA was assessed in male and female Wistar rats. Results A high A2aR binding affinity and high A1R selectivity were recorded for FLUDA (KiA2aR= 0.60 nM and KiA1R= XX nM). The two-step one-pot automated radiosynthesis of [18F]FLUDA was successfully established (radiochemical yield: 9±1%; radiochemical purity: ≥98%; molar activity= 69

Introduction The A2AR has emerged as a potential therapeutic target due to its involvement in basic functions of the neuronal, cardiovascular and immune systems. Blockade of A2AR is regarded as potential tool related to CAR T-cell immunotherapy of cancer. Furthermore, A2AR are believed to regulate myocardial oxygen demand and to increase coronary circulation by vasodilation. With regard to Parkinson’s disease A2AR antagonists, such as the FDA approved Nourianz®, are used as an adjunctive treatment to levopoda®. Therefore noninvasive imaging to monitor changes of receptor density and/or occupancy during the A2aR-tailored therapy is of utmost importance. We recently developed the A2AR PET radiotracer [18F]FLUDA which demonstrated superior pharmacokinetic properties among the radiotracers available. Towards its clinical translation, an automated radiosynthesis was developed and the radiotracer was fully characterized in vitro and in vivo including toxicity and dosimetry1 studies. Methods The binding affinity (Ki) of FLUDA towards the human A2AR and A1R subtypes was estimated in vitro by competitive radioligand binding assays. In addition, selectivity studies were performed. An automated two-step one-pot radiosynthesis of [18F]FLUDA was developed. In vitro autoradiography was performed on cryosections of mice brain. Dynamic PET/MR studies under baseline and blocking conditions were assessed. The time-activity curves of the SUV ratio (SUVR) of striatum over cerebellum were used as measure for specific uptake. Metabolism was investigated in CD-1 mice via radio-HPLC analysis of extracted plasma and brain samples. Single-dose acute toxicity of FLUDA was assessed in male and female Wistar rats. Results A high A2aR binding affinity and high A1R selectivity were recorded for FLUDA (KiA2aR= 0.60 nM and KiA1R= XX nM). The two-step one-pot automated radiosynthesis of [18F]FLUDA was successfully established (radiochemical yield: 9±1%; radiochemical purity: ≥98%; molar activity= 69

The adenosine A2A receptor (A2AR) is regarded as a particularly appropriate target for non-dopaminergic treatment of Parkinson’s disease (PD). An increased A2AR availability has been found in the human striatum at early stages of PD and in patients with PD and dyskinesias. The aim of this small animal positron emission tomography/magnetic resonance (PET/MR) imaging study was to investigate whether rotenone-treated mice reflect the aspect of striatal A2AR upregulation in PD. For that purpose, we selected the known A2AR-specific radiotracer [18F]FESCH and developed a simplified two-step one-pot radiosynthesis. PET images showed a high uptake of [18F]FESCH in the mouse striatum. Concomitantly, metabolism studies with [18F]FESCH revealed the presence of a brain-penetrant radiometabolite. In rotenone-treated mice, a slightly higher striatal A2AR binding of [18F]FESCH was found. Nonetheless, the correlation between the increased A2AR levels within the proposed PD animal model remains to be further investigated.

Die Erfindung betrifft eine Verbindung der allgemeinen Formel I worin die Reste X1a, X1b, X2a, X2b, X3a, X3b, X4a, X4b, X5a und X5b unabhängig voneinander jeweils Wasserstoff oder Deuterium sind, mit der Maßgabe, dass zumindest einer der Reste X1a, X1b, X2a, X2b, X3a, X3b, X4a, X4b, X5a und X5b Deuterium ist.

Die Erfindung betrifft eine Verbindung der allgemeinen Formel I oder ein pharmazeutisch akzeptables Salz davon, wobei A1, A2 und A3 unabhängig voneinander jeweils CH oder N sind; R1 -OR2 oder eine (3-Methyloxetan-3-yl)methyloxy-Gruppe ist, wobei R2 eine substituierte oder unsubstituierte Alkylgruppe mit 1 bis 12 Kohlenstoffatomen ist; X1 aus der Gruppe ausgewählt ist, die aus Wasserstoff, Halogen, Methyl -NO2 und einer kationischen Trialkylammoniumgruppe besteht; X2 aus der Gruppe ausgewählt ist, die aus Halogen, -NO2, einer Boronsäureester-Gruppe, einer Aryliodonium-Gruppe und einer spirocyclischen Iodoniumylid-Gruppe besteht, wobei die Boronsäureester-Gruppe eine Boronsäurepinakolester-Gruppe ist.

Die Erfindung betrifft eine Verbindung der allgemeinen Formel I worin eine Phenylgruppe oder eine Pyridylgruppe ist, R1 aus der Gruppe ausgewählt ist, die aus Wasserstoff, Halogen und -CN besteht; R2 aus der Gruppe ausgewählt ist, die aus Fluor, einer fluorierten Alkylgruppe mit 1 bis 12 Kohlenstoffatomen, einer fluorierten Alkoxygruppe mit 1 bis 12 Kohlenstoffatomen und einer fluorierten Ethergruppe besteht; Z -(CH2)n- oder -(CH2)m-C(O)-(CH2)p- ist, wobei n eine Ganzzahl von 1 bis 12 ist und wobei m und p gleich oder verschieden sein können und jeweils 0 oder eine Ganzzahl von 1 bis 12 sind.